Nanoparticle Formulations in Pulmonary Drug Delivery

被引:214
作者
Bailey, Mark M. [1 ]
Berkland, Cory J. [1 ,2 ]
机构
[1] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66047 USA
[2] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
关键词
nanotechnology; pulmonary medicine; nanoparticle formulations; nanoparticle toxicity; DRY POWDER INHALER; IN-VITRO; BIODEGRADABLE NANOPARTICLES; ALVEOLAR MACROPHAGES; GENE DELIVERY; INSULIN; INHALATION; LIPOSOMES; PARTICLES; NANOSUSPENSIONS;
D O I
10.1002/med.20140
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
The advent of nanotechnology has reignited interest in the lungs as a major route of drug delivery for both systemic and local treatments. The large surface area of the lungs and the minimal barriers impeding access to the lung periphery make this organ a suitable portal for a variety of therapeutic interventions. Nanoparticles provide new formulation options for both dispersed liquid droplet dosage forms such as metered dose inhalers and nebulizers, and dry powder formulations. Nanoparticle formulations have many advantages over traditional dosage forms, such as enhanced dissolution properties and the potential for intracellular drug delivery. Specifically, pure drug nanoparticles, polymeric nanoparticles, polyelectrolyte complexes, and drug-loaded liposomes offer some encouraging results for delivering drugs to and through the lungs. Methods are also being investigated to produce nanoparticles with properties suitable for improving access to the peripheral lung. Traditional techniques such as spray drying and grinding, and more recent advances in supercritical fluid extraction, precipitation, and solvent extraction have been employed to produce nanoparticle formulations for pulmonary delivery. Here, the benefits of nanoparticle formulations and current progress are compared in light of the practical encumbrances of producing formulations, and possible toxicological effects of these materials. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 196-212, 2009
引用
收藏
页码:196 / 212
页数:17
相关论文
共 84 条
[1]
Technologies that deliver [J].
Basu, P .
NATURE MEDICINE, 2003, 9 (09) :1100-1101
[2]
Bhandari KH, 2007, J PHARM PHARM SCI, V10, P278
[3]
Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery [J].
Bhavane, R ;
Karathanasis, E ;
Annapragada, AV .
JOURNAL OF CONTROLLED RELEASE, 2003, 93 (01) :15-28
[4]
PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium [J].
Bivas-Benita, M ;
Romeijn, S ;
Junginger, HE ;
Borchard, G .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (01) :1-6
[6]
Brocklebank D, 2001, Health Technol Assess, V5, P1
[7]
Comparison of permeation enhancing strategies for an oral factor Xa inhibitor using the Caco-2 cell monolayer model [J].
Bruesewitz, Carsten ;
Funke, Adrian ;
Kuhland, Urte ;
Wagner, Torsten ;
Lipp, Ralph .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 64 (02) :229-237
[8]
Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases [J].
Brzoska, M ;
Langer, K ;
Coester, C ;
Loitsch, S ;
Wagner, TOF ;
Mallinckrodt, CV .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 318 (02) :562-570
[9]
Bunnag C, 2007, ASIAN PAC J ALLERGY, V25, P99
[10]
Cha, 2007, J MICROBIOL BIOTECHN, V17, P1573